JP2015533084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533084A5 JP2015533084A5 JP2015534816A JP2015534816A JP2015533084A5 JP 2015533084 A5 JP2015533084 A5 JP 2015533084A5 JP 2015534816 A JP2015534816 A JP 2015534816A JP 2015534816 A JP2015534816 A JP 2015534816A JP 2015533084 A5 JP2015533084 A5 JP 2015533084A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- marker
- item
- marker gene
- gene set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 96
- 206010028980 Neoplasm Diseases 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 102000038427 NEDD8-activating enzyme E1 Human genes 0.000 claims description 52
- 108091007790 NEDD8-activating enzyme E1 Proteins 0.000 claims description 52
- 239000003112 inhibitor Substances 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 32
- 238000010238 partial least squares regression Methods 0.000 claims description 17
- 230000037361 pathway Effects 0.000 claims description 13
- 230000035945 sensitivity Effects 0.000 claims description 13
- -1 1- Substituted methyl Chemical group 0.000 claims description 10
- 230000002489 hematologic effect Effects 0.000 claims description 10
- 230000019491 signal transduction Effects 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 claims description 4
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 4
- 102000019997 adhesion receptor Human genes 0.000 claims description 4
- 108010013985 adhesion receptor Proteins 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 2
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical class COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- MPUQHZXIXSTTDU-QXGSTGNESA-N sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester Chemical compound C1[C@H](O)[C@H](COS(=O)(=O)N)C[C@H]1N1C2=NC=NC(N[C@@H]3C4=CC=CC=C4CC3)=C2C=C1 MPUQHZXIXSTTDU-QXGSTGNESA-N 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708349P | 2012-10-01 | 2012-10-01 | |
| US61/708,349 | 2012-10-01 | ||
| PCT/US2013/062902 WO2014055543A2 (en) | 2012-10-01 | 2013-10-01 | Biomarkers and methods to predict response to inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533084A JP2015533084A (ja) | 2015-11-19 |
| JP2015533084A5 true JP2015533084A5 (https=) | 2017-02-09 |
| JP6486826B2 JP6486826B2 (ja) | 2019-03-20 |
Family
ID=50435571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534816A Expired - Fee Related JP6486826B2 (ja) | 2012-10-01 | 2013-10-01 | 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10662477B2 (https=) |
| EP (1) | EP2904115B1 (https=) |
| JP (1) | JP6486826B2 (https=) |
| CN (1) | CN104822844B (https=) |
| CA (1) | CA2886783A1 (https=) |
| WO (1) | WO2014055543A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238900B2 (ja) | 2011-10-28 | 2017-11-29 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎａｅ阻害物質に対する応答のバイオマーカー |
| US10210312B2 (en) * | 2013-02-03 | 2019-02-19 | Youscript Inc. | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
| CN104820873B (zh) * | 2015-05-13 | 2017-12-26 | 中国环境科学研究院 | 一种基于金属定量构效关系的淡水急性基准预测方法 |
| WO2017011439A1 (en) * | 2015-07-13 | 2017-01-19 | Biodesix, Inc. | Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
| US20180231561A1 (en) * | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| GB201521481D0 (en) * | 2015-12-04 | 2016-01-20 | Healx Ltd | Prognostic system |
| US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
| AU2017261353A1 (en) * | 2016-05-05 | 2018-11-08 | Nantomics, Llc | Checkpoint failure and methods therefor |
| WO2018129301A1 (en) | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
| WO2019060536A1 (en) | 2017-09-21 | 2019-03-28 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| US12094587B2 (en) | 2018-03-29 | 2024-09-17 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
| US20210215697A1 (en) * | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| CN110885830A (zh) * | 2018-09-07 | 2020-03-17 | 安徽华大医学检验所有限公司 | Fn1基因突变及其应用 |
| CN109411015B (zh) * | 2018-09-28 | 2020-12-22 | 深圳裕策生物科技有限公司 | 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质 |
| CN109762911B (zh) * | 2019-02-21 | 2020-12-01 | 华中农业大学 | Ptprj基因作为猪免疫相关性状的分子标记及其应用 |
| JP7438693B2 (ja) | 2019-09-02 | 2024-02-27 | キヤノンメディカルシステムズ株式会社 | 診療支援装置 |
| GB2595718A (en) * | 2020-06-04 | 2021-12-08 | Cancer Research Tech Ltd | Methods for predicting treatment response in cancers |
| CA3193688A1 (en) * | 2020-10-09 | 2022-04-14 | Vladimir Lazar | Novel prediction method and gene signatures for the treatment of cancer |
| CN112415206B (zh) * | 2020-10-23 | 2023-08-18 | 上海良润生物医药科技有限公司 | 外泌体中的cd171蛋白作为肿瘤转移诊断标志物的应用 |
| CN113046357B (zh) * | 2021-01-25 | 2023-05-16 | 柳州市柳铁中心医院 | 一种乐伐替尼耐药基因dusp9、其筛选方法及应用 |
| CN114045336B (zh) * | 2021-09-28 | 2024-01-02 | 中国人民解放军空军军医大学 | Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用 |
| US12254987B2 (en) * | 2023-03-23 | 2025-03-18 | Certis Oncology Solutions, Inc. | Artificial intelligence for identifying one or more predictive biomarkers |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| DE3924454A1 (de) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips) |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU661270B2 (en) | 1990-03-05 | 1995-07-20 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0834575B1 (en) | 1990-12-06 | 2001-11-28 | Affymetrix, Inc. (a Delaware Corporation) | Identification of nucleic acids in samples |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
| EP0636186B1 (en) | 1992-04-03 | 1998-11-25 | The Perkin-Elmer Corporation | Probe composition and method |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| DE4311230C2 (de) | 1993-04-02 | 1996-12-19 | Mannesmann Ag | Nicht-spurgebundenes Fahrzeug mit Elektromotor |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| EP0758403B1 (en) | 1994-05-05 | 1998-06-24 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US6096778A (en) | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| US7013221B1 (en) | 1999-07-16 | 2006-03-14 | Rosetta Inpharmatics Llc | Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays |
| US6077674A (en) | 1999-10-27 | 2000-06-20 | Agilent Technologies Inc. | Method of producing oligonucleotide arrays with features of high purity |
| FR2828884B1 (fr) | 2001-08-27 | 2005-09-09 | Centre Nat Rech Scient | Hydrazinopeptoides et leurs utilisations dans le traitement des cancers |
| US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| ATE448232T1 (de) | 2003-02-14 | 2009-11-15 | Intermed Discovery Gmbh | Substituierte heterozyklen |
| KR20060026052A (ko) | 2003-06-20 | 2006-03-22 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법 |
| TW589273B (en) | 2003-07-31 | 2004-06-01 | Quanta Comp Inc | Packaging carton |
| FR2859995A1 (fr) | 2003-09-23 | 2005-03-25 | Centre Nat Rech Scient | Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers |
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| WO2005105826A1 (ja) | 2004-04-28 | 2005-11-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | チロペプチンａ類縁体 |
| EP2030981B1 (en) | 2004-05-10 | 2014-07-09 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| US20070249540A1 (en) | 2004-05-24 | 2007-10-25 | Adonia Papathanassiu | Methods for Inhibiting Proteasome and Heat Shock Protein 90 |
| GB0412301D0 (en) | 2004-06-02 | 2004-07-07 | Diagenic As | Product and method |
| US20060088471A1 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Compounds for enzyme inhibition |
| PT1848718E (pt) | 2005-02-04 | 2012-10-11 | Millennium Pharm Inc | Inibidores de enzimas de activação e1 |
| US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| KR101450535B1 (ko) | 2006-02-02 | 2014-10-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ１ 활성화 효소의 억제제 |
| EA201501088A1 (ru) | 2006-08-08 | 2017-01-30 | Миллениум Фармасьютикалз, Инк. | Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов |
| WO2009099991A2 (en) * | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| SG175929A1 (en) | 2009-05-14 | 2011-12-29 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| MX2011013578A (es) | 2009-06-19 | 2012-01-20 | Merck Patent Gmbh | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. |
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| CA2796251C (en) | 2010-04-13 | 2019-05-14 | Cellular Dynamics International, Inc. | Hepatocyte production by forward programming |
| WO2011139345A2 (en) * | 2010-04-29 | 2011-11-10 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
| US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
| US20120010230A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| US9506926B2 (en) * | 2011-02-18 | 2016-11-29 | The Regents Of The University Of California | Molecular predictors of therapeutic response to specific anti-cancer agents |
| JP6238900B2 (ja) | 2011-10-28 | 2017-11-29 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎａｅ阻害物質に対する応答のバイオマーカー |
-
2013
- 2013-10-01 EP EP13843965.8A patent/EP2904115B1/en not_active Not-in-force
- 2013-10-01 JP JP2015534816A patent/JP6486826B2/ja not_active Expired - Fee Related
- 2013-10-01 WO PCT/US2013/062902 patent/WO2014055543A2/en not_active Ceased
- 2013-10-01 CN CN201380061933.5A patent/CN104822844B/zh not_active Expired - Fee Related
- 2013-10-01 CA CA2886783A patent/CA2886783A1/en not_active Abandoned
- 2013-10-01 US US14/432,587 patent/US10662477B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533084A5 (https=) | ||
| McKerrow et al. | LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint | |
| Borisov et al. | Signaling pathways activation profiles make better markers of cancer than expression of individual genes | |
| Alsaleem et al. | A novel prognostic two-gene signature for triple negative breast cancer | |
| JP2010500565A5 (https=) | ||
| Xiong et al. | A structurally informed human protein–protein interactome reveals proteome-wide perturbations caused by disease mutations | |
| Aloraifi et al. | Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer | |
| Dudbridge et al. | Predictive accuracy of combined genetic and environmental risk scores | |
| JP2017503527A5 (https=) | ||
| HRP20191182T1 (hr) | Identifikacija tumorsko-zaštitnih epitopa za liječenje karcinoma | |
| Liu et al. | Heterogeneous expression of tandem‐pore K+ channel genes in adult and embryonic rat heart quantified by real‐time polymerase chain reaction | |
| Worst et al. | The EEF1A2 gene expression as risk predictor in localized prostate cancer | |
| Weng et al. | Poly (A) code analyses reveal key determinants for tissue-specific mRNA alternative polyadenylation | |
| KR102265529B1 (ko) | 복합 유전 정보 네트워크 분석에 기반한 질병 위험도 진단 방법 | |
| Che et al. | A new explained-variance based genetic risk score for predictive modeling of disease risk | |
| Zhong et al. | MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia | |
| Siwo et al. | Predicting functional and regulatory divergence of a drug resistance transporter gene in the human malaria parasite | |
| Dong et al. | Selection of reference genes in liproxstatin-1-treated K562 Leukemia cells via RT-qPCR and RNA sequencing | |
| Olivieri et al. | Analysis of RNA processing directly from spatial transcriptomics data reveals previously unknown regulation | |
| Ely et al. | The impact of natural selection on the evolution and function of placentally expressed galectins | |
| Antonini et al. | Research techniques made simple: identification and characterization of long noncoding RNA in dermatological research | |
| Yue et al. | RETRACTED: The predictive efficacy of programmed cell death in immunotherapy of melanoma: A comprehensive analysis of gene expression data for programmed cell death biomarker and therapeutic target discovery | |
| Kim et al. | Biomarker detection for the diagnosis of lymph node metastasis from oral squamous cell carcinoma | |
| CN114400069A (zh) | 一种用于预测三阴乳腺癌化疗响应的标志物及模型 | |
| Hernandez-Suarez et al. | Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs |